Home
Storia in 2 fonti
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on the acquisition of Organon, with completion targeted for the last quarter of FY2027. This strategic move is set to enhance Sun Pharma's global presence and product portfolio across key therapeutic areas.
- ·
economictimes.indiatimes.com
Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets. Brokerages…
- ·
thehindubusinessline.com
Sun Pharma Q4 net profit up 26% at ₹2,714 crore
Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.
- ·
Sun Pharma Q4 net profit up 26 per cent
Sun Pharma reports a 26% rise in Q4 net profit, driven by strong sales and ongoing investments in innovative products.
- ·
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration deal
Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. Significant progress is being made on…